What Is Psoriatic Arthritis? Symptoms, Diagnosis, and Treatment

Psoriatic arthritis (PsA) is a chronic inflammatory disease that causes joint pain, swelling, and stiffness in people with psoriasis. Up to 30% of people with psoriasis develop PsA, and it can cause permanent joint damage if untreated. Early diagnosis and treatment with medications like biologics can protect your joints and reduce inflammation in both skin and joints at the same time.

If you have psoriasis and your joints have started hurting, pay attention. Joint pain with psoriasis isn’t just “getting older.” It could be psoriatic arthritis, where the same overactive immune response that attacks your skin also targets your joints. Catching it early matters more than most people realize. Rheumatologists say there is a two-year window after symptoms start. Treating during that time can prevent permanent joint damage.

What Is Psoriatic Arthritis?

Psoriatic arthritis is an autoimmune disease. The immune system wrongly attacks healthy joint tissue, tendons, and the spots where tendons connect to bone. It belongs to a group of conditions called spondyloarthropathies. It is closely linked to [psoriasis](/what-is-psoriasis/), which causes red, scaly patches.

Your immune system is supposed to fight infections. In PsA, it misfires and creates inflammation in your joints, tendons, and sometimes your spine. The result is pain, swelling, and stiffness that can range from mild to severe.

PsA affects about 1 to 2 million Americans, per the National Psoriasis Foundation. In about 85% of cases, skin psoriasis shows up first, often as one of several types of psoriasis. Joint symptoms follow 7 to 12 years later. But about 15% of people get joint problems before any skin changes appear. This makes diagnosis harder.

The disease shows up in five patterns. Knowing which one you have helps guide treatment:

Asymmetric oligoarthritis affects fewer than five joints on one side of the body. This is the most common pattern at diagnosis, accounting for about 35% of cases.

Symmetric polyarthritis looks like rheumatoid arthritis. It affects matching joints on both sides. It accounts for roughly 25% of PsA cases and tends to be more severe.

Spondylitis primarily affects the spine and sacroiliac joints in the lower back, causing stiffness and pain. About 5% of people with PsA have this as their main pattern.

Distal interphalangeal (DIP) type targets the small joints nearest your fingernails and toenails. This pattern is strongly associated with nail psoriasis.

Arthritis mutilans is the rarest and most severe form, affecting fewer than 5% of people with PsA. It causes severe bone erosion and can shorten the fingers, a condition called “telescoping digits.”

Many people have overlapping patterns, and the pattern can shift over time.

What Are the Symptoms of Psoriatic Arthritis?

Psoriatic arthritis symptoms include joint pain, swelling, and morning stiffness lasting 30 minutes or more. Beyond the joints, PsA causes enthesitis (pain where tendons meet bone) and dactylitis (sausage-like swelling of whole fingers or toes). It also causes nail pitting, fatigue, and sometimes eye inflammation called uveitis.

PsA does more than hurt your joints. It’s a systemic disease, meaning it can affect your whole body. Here’s what to watch for.

Joint Symptoms

The joints most commonly affected are in the fingers, toes, wrists, knees, and ankles. Pain is typically worse in the morning or after sitting still for a while. You might notice that your joints feel stiff for 30 minutes or longer when you wake up, and the stiffness improves as you move.

Swelling in PsA tends to look different from other types of arthritis. Affected joints may appear red, warm, and visibly puffy.

Enthesitis

This is inflammation at the entheses, the spots where tendons and ligaments connect to bone. The Achilles tendon (back of the heel) and the plantar fascia (bottom of the foot) are the most common sites. Enthesitis affects up to 35% of people with PsA, per a 2020 review in Rheumatology and Therapy. It can be one of the earliest signs.

Dactylitis

Sometimes called “sausage digits,” dactylitis causes an entire finger or toe to swell uniformly. It looks distinctly different from the localized swelling you’d see with a single swollen joint. Dactylitis occurs in about 40% to 50% of people with PsA and is considered a hallmark feature of the disease.

Nail Changes

Nail psoriasis and PsA are closely linked. You might notice tiny pits or dents in your nails, ridges, or thickening. The nail may also lift from the nail bed (onycholysis). About 80% of people with PsA have nail changes. That compares to roughly 50% of people with skin psoriasis alone.

Eye Inflammation

Uveitis, inflammation of the middle layer of the eye, affects about 7% of people with PsA. Symptoms include eye redness, pain, blurred vision, and sensitivity to light. Uveitis requires prompt treatment from an ophthalmologist to prevent vision loss.

Fatigue

Persistent, bone-deep exhaustion affects a majority of people with PsA. A 2019 study in the Journal of Rheumatology found fatigue and pain were the top concerns of people with PsA. It doesn’t always correlate with disease activity, and it doesn’t go away with a good night’s sleep.

If you have psoriasis and notice any combination of these symptoms, see a rheumatologist. Don’t wait for the symptoms to become severe.

How Do Doctors Diagnose Psoriatic Arthritis?

Doctors diagnose psoriatic arthritis using the CASPAR criteria, which evaluate joint inflammation, skin psoriasis (current or history), nail changes, dactylitis, negative rheumatoid factor blood test, and bone changes on imaging. No single lab test confirms PsA, so diagnosis relies on a combination of physical exam, blood work, and imaging.

Diagnosing PsA can be hard because it overlaps with other types of arthritis. The CASPAR criteria are the most widely used tool for diagnosis. They were developed by global researchers and published in Arthritis & Rheumatism.

To meet CASPAR criteria, you need inflammatory joint disease plus at least 3 points from these categories:

• Current psoriasis (2 points), history of psoriasis (1 point), or family history of psoriasis (1 point)
• Nail changes like pitting, onycholysis, or hyperkeratosis (1 point)
• Current dactylitis or history of dactylitis (1 point)
• Negative rheumatoid factor blood test (1 point)
• Juxta-articular new bone formation on X-ray, visible near joints (1 point)

Blood Tests

There’s no single blood test for PsA, but several help narrow the diagnosis. Rheumatoid factor (RF) and anti-CCP antibodies are usually negative in PsA. This helps tell it apart from rheumatoid arthritis. Markers like C-reactive protein (CRP) and sed rate (ESR) may be high. But they’re normal in some people with active PsA.

Imaging

Different imaging methods reveal different aspects of PsA:

X-rays can show joint erosion, new bone growth, and the distinctive “pencil-in-cup” deformity where bone erosion narrows one side of a joint while the other side widens. These changes typically appear in more advanced disease.

MRI finds inflammation in soft tissues, entheses, and bone marrow before damage shows up on X-ray. It’s especially useful for finding sacroiliitis (inflammation in the lower back joints).

Musculoskeletal ultrasound can find joint lining inflammation, enthesitis, and early erosions in real time during your visit. A 2022 study in Annals of the Rheumatic Diseases found ultrasound spotted joint inflammation in 30% of psoriasis patients who had no joint symptoms yet.

Why Early Detection Matters

Research in Annals of the Rheumatic Diseases shows that starting treatment within two years of symptoms leads to better long-term results than waiting. After that window, joint damage becomes harder to prevent. If you have psoriasis and get new joint pain, stiffness, or swelling, ask your dermatologist for a referral to a rheumatologist. Don’t assume it’s something else.

How Is Psoriatic Arthritis Treated?

PsA treatment usually starts with NSAIDs for mild symptoms. For moderate to severe disease, doctors move to DMARDs and biologics. Biologics targeting TNF, IL-17, IL-23, and JAK pathways can treat both skin psoriasis and joint disease simultaneously. The goal is remission or minimal disease activity.

Treatment for PsA has improved dramatically over the past two decades. Your rheumatologist will make a plan based on how many joints are affected, how bad your symptoms are, and whether you have major skin disease too.

NSAIDs

For mild PsA with a few sore joints, anti-inflammatory drugs like ibuprofen, naproxen, or celecoxib may control pain and swelling. They don’t slow disease progression, so your doctor will monitor closely for worsening.

Conventional DMARDs

Methotrexate is the most commonly prescribed conventional DMARD for PsA. It helps with joint inflammation and skin psoriasis, taken once weekly as a pill or injection. A 2019 Cochrane review found modest evidence of benefit for PsA joints, though its track record for skin disease is well established.

Sulfasalazine and leflunomide are options when methotrexate isn’t tolerated. They work primarily on peripheral joints and have less effect on skin or spine involvement.

Biologics

Biologics have changed what’s possible for people with PsA. These are targeted drugs given by injection or infusion. They block specific immune proteins that drive inflammation.

TNF inhibitors were the first biologics approved for PsA. Options include adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade), golimumab (Simponi), and certolizumab (Cimzia). In trials, TNF inhibitors reach ACR20 response (at least 20% symptom improvement) in about 55% to 60% of people treated.

IL-17 inhibitors target a different inflammatory pathway. Secukinumab (Cosentyx) showed a 51% ACR20 response rate at 24 weeks in the FUTURE 2 trial, and it also improved enthesitis and dactylitis. Ixekizumab (Taltz) produced similar results in the SPIRIT-P1 trial, with a 58% ACR20 response rate at 24 weeks. Both work well for skin disease too.

IL-23 inhibitors are a newer option. Guselkumab (Tremfya) achieved a 64% ACR20 response at 24 weeks in the DISCOVER-2 trial, one of the highest rates seen in PsA trials. Risankizumab (Skyrizi) received FDA approval for PsA in January 2024 based on the KEEPsAKE trials, showing a 55% to 57% ACR20 response rate. IL-23 inhibitors tend to produce strong skin clearance alongside joint improvement.

JAK Inhibitors

Tofacitinib (Xeljanz) and upadacitinib (Rinvoq) are pills that block JAK enzymes tied to inflammation. They work for PsA but carry boxed warnings about higher risks of blood clots, heart events, and cancer. Your rheumatologist will discuss these with you.

Choosing Between Treatments

Your doctor will weigh several factors: how many joints are involved, whether your spine is affected, your skin severity, and your other health conditions. Many of these biologics treat both skin psoriasis and PsA at the same time. This can simplify your treatment plan. If you’re already on a biologic for skin psoriasis that is also approved for PsA, that same drug may cover both.

Exercise and Physical Therapy for Psoriatic Arthritis

Regular activity helps reduce stiffness, strengthen muscles around affected joints, and boost your energy. A 2021 study in RMD Open found that exercise improved physical function, pain, and fatigue in people with PsA. It did not worsen joint inflammation.

Recommended activities include:

• Low-impact aerobics like walking, swimming, or cycling to build cardiovascular fitness without stressing joints
• Strength training with light weights or resistance bands to stabilize joints
• Range-of-motion exercises and gentle stretching to maintain flexibility
• Aquatic therapy, which uses water buoyancy to reduce joint stress during movement

A physical therapist who knows inflammatory arthritis can create a program for your affected joints and fitness level. If your fingers or wrists are involved, an occupational therapist can help with hand exercises and joint protection tips.

When Should You See a Rheumatologist?

See a rheumatologist if you have psoriasis and develop joint pain, stiffness, or swelling lasting more than a few weeks. Other warning signs: morning stiffness lasting 30 minutes or more, sausage-like swelling of a finger or toe, heel or foot pain that rest doesn’t fix, or nail changes with joint symptoms.

If you have psoriasis and develop any of the following, request a referral to a rheumatologist:

• Joint pain, stiffness, or swelling that lasts more than a few weeks
• Morning stiffness lasting 30 minutes or longer
• A finger or toe that swells along its entire length
• Heel pain or bottom-of-foot pain that doesn’t respond to rest
• Lower back pain and stiffness, especially if it’s worse in the morning and improves with movement
• Nail changes alongside any joint symptoms

Dermatologists should check for joint symptoms at every psoriasis visit. If yours doesn’t ask, bring it up. The PASQ and PEST are validated screening tools your dermatologist can use in under two minutes.

Frequently Asked Questions

Does everyone with psoriasis get psoriatic arthritis?

No. About 30% of people with psoriasis develop PsA. Having severe skin disease, nail psoriasis, or a family history of PsA increases your risk, but many people with psoriasis never develop joint problems.

Can you have psoriatic arthritis without psoriasis?

Yes, though it’s uncommon. About 15% of people develop joint symptoms before any skin changes appear. A family history of psoriasis may help doctors make the connection.

Is psoriatic arthritis worse than rheumatoid arthritis?

They’re different diseases with different patterns. PsA can affect the spine, entheses, and nails in ways that rheumatoid arthritis doesn’t. Some people with PsA have mild symptoms managed with minimal medication, while others have aggressive disease. Severity varies widely in both conditions.

Can psoriatic arthritis be cured?

There is no cure for PsA. Current treatments can control inflammation, relieve symptoms, and prevent joint damage. Many people achieve remission or low disease activity with biologics and other medications.

What happens if psoriatic arthritis goes untreated?

Without treatment, PsA can cause permanent joint damage, bone erosion, and loss of function. A 2015 study in Annals of the Rheumatic Diseases found that nearly half of people with PsA had bone erosion visible on X-ray within two years of symptom onset if untreated. Early treatment is the best way to prevent irreversible damage.

Does diet affect psoriatic arthritis?

Some evidence suggests that a Mediterranean-style diet rich in fish, vegetables, and olive oil may help reduce inflammation. Obesity worsens PsA symptoms and can reduce how well biologics work. A 2020 study in the Journal of the American Academy of Dermatology found that weight loss of 5% or more improved treatment response in people with PsA and obesity.

Are biologics safe for long-term use?

Biologics have been used for PsA since the early 2000s, with over 20 years of safety data for TNF inhibitors. They do increase infection risk because they suppress parts of the immune system. Your rheumatologist will monitor you with regular blood tests and screen for tuberculosis before starting treatment. Most people tolerate biologics well over many years.

Can psoriatic arthritis affect organs other than joints and skin?

PsA increases your risk of cardiovascular disease, metabolic syndrome, inflammatory bowel disease, and depression. Regular screening for heart disease risk factors and mental health is part of good PsA management.

Sources and References

1. National Psoriasis Foundation. “About Psoriatic Arthritis.” psoriasis.org/about-psoriatic-arthritis/
2. Ritchlin CT, Colbert RA, Gladman DD. “Psoriatic Arthritis.” New England Journal of Medicine. 2017;376(10):957-970.
3. Alinaghi F, et al. “Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis.” Journal of the American Academy of Dermatology. 2019;80(1):251-265.
4. Taylor W, et al. “Classification criteria for psoriatic arthritis: development of new criteria from a large international study.” Arthritis & Rheumatism. 2006;54(8):2665-2673.
5. McInnes IB, et al. “Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2).” Annals of the Rheumatic Diseases. 2015;74(6):1133-1139.
6. Mease PJ, et al. “Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis (SPIRIT-P1).” Annals of the Rheumatic Diseases. 2017;76(1):79-87.
7. Deodhar A, et al. “Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-2).” The Lancet. 2020;395(10230):1126-1136.
8. Kristensen LE, et al. “Efficacy and safety of risankizumab for active psoriatic arthritis (KEEPsAKE 1 and KEEPsAKE 2).” Annals of the Rheumatic Diseases. 2022;81(5):617-624.
9. Gladman DD, et al. “Psoriatic arthritis: epidemiology, clinical features, course, and outcome.” Annals of the Rheumatic Diseases. 2005;64(suppl 2):ii14-ii17.
10. Haroon M, et al. “Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis.” Annals of the Rheumatic Diseases. 2015;74(6):1045-1050.
11. Gisondi P, et al. “Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy.” Journal of the American Academy of Dermatology. 2020;82(6):1407-1409.
12. Husted JA, et al. “Cardiovascular and other comorbidities in patients with psoriatic arthritis.” Arthritis Care & Research. 2011;63(12):1729-1735.
13. Polachek A, et al. “Musculoskeletal ultrasound detects subclinical enthesitis and synovitis in psoriasis patients without musculoskeletal complaints.” Annals of the Rheumatic Diseases. 2022;81(2):252-258.
14. Krajewska-Wlodarczyk M, et al. “Enthesitis in psoriatic arthritis.” Rheumatology and Therapy. 2020;7:687-698.
15. Roger-Silva D, et al. “Exercise interventions for psoriatic arthritis.” RMD Open. 2021;7(2):e001657.

Psoriasis Daily is strictly a news and information website about psoriasis and psoriatic arthritis. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.